Gowling WLG advises argenx on $625 million collaboration with AbbVie to develop ARGX-115

3 minute read
21 April 2016

Gowling WLG's Life Sciences team has advised argenx on its collaboration with global biopharmaceutical company AbbVie to develop ARGX-115, a potential treatment for cancer.

Patrick Duxbury, head of life sciences, worked with associate Elwin Morgan on the collaboration agreement. Patrick worked closely with senior VP of business development at argenx, Dr Debbie Allen and with CEO Tim van Hauwermeiren.

Belgium-based biotech company argenx focuses on creating and developing therapeutic antibodies to treat cancer and severe autoimmune diseases. ARGX-115 is argenx's preclinical-stage human antibody which has the potential to block certain immune-suppressive pathways that allow cancers to grow.

Tim van Hauwermeiren, Chief Executive Officer of argenx said:  "We believe ARGX-115 has the potential to advance immuno-oncology by selectively targeting tumor immune escape pathways. We are proud to develop and commercialize ARGX-115 through collaboration with AbbVie, a global leader in oncology and are grateful for the expertise of Gowling WLG in enabling this transaction."

Patrick Duxbury added: "We've acted on many deals for argenx over the last six years and we're pleased to have been involved in this one, a highly strategic collaboration which could represent a significant  step forward both for argenx and in the development of novel cancer treatments."

Under the terms of the agreement, argenx will receive an upfront payment of $40 million from AbbVie for the exclusive option to license ARGX-115 and near-term preclinical milestones of $20 million.

argenx is also eligible to receive additional development, regulatory and commercial payments up to $625 million upon achievement of pre-determined milestones as well as tiered, up to double-digit royalties on net sales upon commercialisation.

Gowling WLG's Life Sciences team comprises almost 200 professionals in 18 offices around the globe with full-service expertise in IP, corporate, competition & EU, regulatory and dispute resolution matters. The team's recent highlights include advising Heptares on its $3.375 billion global R&D and commercialisation partnership.

Patrick Duxbury was recently named one of the world's top six life sciences: transactional lawyers in Who's Who Legal: Life Sciences 2016.

Reed Smith US acted for AbbVie.

NOT LEGAL ADVICE. Information made available on this website in any form is for information purposes only. It is not, and should not be taken as, legal advice. You should not rely on, or take or fail to take any action based upon this information. Never disregard professional legal advice or delay in seeking legal advice because of something you have read on this website. Gowling WLG professionals will be pleased to discuss resolutions to specific legal concerns you may have.

Related   Life Sciences